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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that involves the death of neurons.
ALS is associated with many gene mutations as previously studied. In order to explore the molecular mechanisms
underlying ALS with C9orf72 mutation, gene expression profiles of ALS fibroblasts and control fibroblasts were
subjected to bioinformatics analysis. Genes with critical functional roles can be detected by a measure of node
centrality in biological networks. In gene co-expression networks, highly connected genes called as candidate hubs
have been associated with key disease-related pathways. Herein, this method was applied to find the hub genes
related to ALS disease.
Methods: Illumina HiSeq microarray gene expression dataset GSE51684 was retrieved from Gene Expression
Omnibus (GEO) database which included four Sporadic ALS, twelve Familial ALS and eight control samples.
Differentially Expressed Genes (DEGs) were identified using the Student’s t test statistical method and gene
co-expression networking. Gene ontology (GO) function and KEGG pathway enrichment analysis of DEGs were
performed using the DAVID online tool. Protein-protein interaction (PPI) networks were constructed by mapping
the DEGs onto protein-protein interaction data from publicly available databases to identify the pathways where
DEGs are involved in. PPI interaction network was divided into subnetworks using MCODE algorithm and was
analyzed using Cytoscape.
Results: The results revealed that the expression of DEGs was mainly involved in cell adhesion, cell-cell signaling, Extra
cellular matrix region GO processes and focal adhesion, neuroactive ligand receptor interaction, Extracellular matrix
receptor interaction. Tumor necrosis factor (TNF), Endothelin 1 (EDN1), Angiotensin (AGT) and many cell adhesion
molecules (CAM) were detected as hub genes that can be targeted as novel therapeutic targets for ALS disease.
Conclusion: These analyses and findings enhance the understanding of ALS pathogenesis and provide references for
ALS therapy.
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Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease that involves the death of neurons [1, 2]. ALS is
often called Lou Gehrig’s disease, after the famous baseball
player who was diagnosed with it. The occurrence of ALS
is two per 100,000 people, and it is estimated that more
than 20,000 Americans may be living with ALS at any
given time. It is worldwide with no racial, ethnic or socio-
economic boundaries and can affect anyone. It affects the
nerve cells in the brain and the spinal cord and is charac-
terized by stiff muscles, muscle twitching and gradually
worsening weakness due to muscles decreasing in size.
Despite intensive research, the clinical and pathophysio-
logical mechanisms of ALS still remain unclear. There are
two types of ALS, sporadic (SALS) and familial (FALS).
90–95 % of ALS cases are sporadic for which the cause is
unknown and 5–10 % are familial, which are inherited [3].
Findings on ALS patients have drawn in numerous genes
related to ALS pathogenesis and have identified diverse
processes, such as excitotoxicity, oxidative stress, cytoske-
letol abnormalities, impaired axonal transport, mitochon-
drial dysfunction and protein aggregation. Presently, ten
genes such as SOD1, ALSIN, SETX, SPG11, FUS, VAPB,
TARDBP, OPTN, ATXN2 and C9orf72 were found to
affect the pathogenesis of ALS [4]. Though SALS and
FALS are clinically and pathophysiologically similar, there
is a requirement of finding the genes involved in FALS
and the molecular mechanism pathways involved in the
mutation of these genes. Till date studies were done to
know the molecular mechanisms and underlying patho-
genesis of ALS disease related to SALS with Superoxide
dismutase 1 (SOD1) mutation [5, 6]. As the study of
SOD1 has led to great advances in proper illustration of
molecular mechanisms underlying in ALS disease, identi-
fying the mutations in other genes and the pathways
involved in these mechanisms is utmost important. Till
date there is no cure for ALS, however the drug riluzole –
the only prescribed drug approved by Food and Drug
Administration (FDA) to treat ALS which prolongs the life
by 2–3 months but do not relieve the symptoms [7, 8].
Improving diagnoses and treatment of this disease is ut-
most essential, as currently there exists no cure for ALS.
C9orf72 mutation is currently the major genetic cause
of ALS disease accounting for approximately 34.2 % of
the familial ALS cases. C9orf72 mutation is a hexanu-
cleotide repeat expansion of the six letter string of
nucleotides GGGGCC. Although nothing about C9orf72
function [9, 10] and the mechanisms by which expanded
repeats cause neurodegeneration are known, C9orf72
RNAs levels were found to be reduced as reported in
tissue samples from patients with C9orf72 expansions
[11–13]. The leading candidate mechanisms by which
expanded repeats cause neurodegeneration are RNA-
mediated toxicity, loss of C9orf72 gene function, or a
combination of the two. In a normal person there would
be few repeats of this nucleotide, but in the person with
C9orf72 mutation this repeat can occur in the order of
hundreds that result in the formation of RNA foci in
white blood cells, fibroblasts, glia and multiple neuronal
cell types. These RNA foci are not present in the spor-
adic ALS and familial ALS caused by other mutations.
This RNA-mediated toxicity is found to play a crucial
role in a variety of repeat expansion disorders by accu-
mulation of expanded transcripts into nuclear RNA foci
[14]. These RNA repeats fold into stable structures and
sequester RNA binding proteins to set off a molecular
cascade leading to neurodegeneration [14]. A loss of
C9orf72 gene function is observed in patients with
expansion by reported reductions of C9orf72 transcript
levels [11–13] Although this reduction to neuronal death
is not established, loss of C9orf72 gene function during
embryonic development is associated with motor deficits
in zebrafish [15].
Lagier-Tourenne et al. have demonstrated the ASO
mediated reduction of C9orf72 RNAs by aggravating the
loss of C9orf72 function [16]. In this view of finding
different molecular mechanisms and pathways related to
C9orf72 mutation in ALS disease, we have used systems
biology approach for the gene expression data to identify
Gene Ontologies (GO) and pathways related to familial
ALS. Genome-wide RNA profiling in fibroblasts from
patients with C9orf72 expansion was studied in the
RNA microarray data [9] used for the present study.
This microarray data retrieved from Gene expression
omnibus (GEO) [17] was screened to identify differen-
tially expressed genes (DEGs) between ALS and control
fibroblasts before and after ASO mediated disease ther-
apy in order to find potential genes for the pathogenesis
of ALS. Gene ontology(GO) enrichment analysis and
Kyoto encyclopedia of Genes and Genomes(KEGG)
pathway analysis was performed, and a protein-protein
interaction (PPI) network was constructed by mapping
the DEGs to the human PPI data. Our research laid a
bridge between the DEGs, the KEGG pathways and the
protein-protein interaction networks which will help for
the development of novel targets for ALS therapeutic
intervention.
Methods
DEGs analysis and Co-expression network
Illumina HiSeq microarray dataset (GSE51684) [16] with
their RPKM (Reads per kilo base per million mapped
reads) values was retrieved from GEO (http://www.ncb
i.nlm.nih.gov/geo/) [17] which was based on the GPL
11154 Illumina HiSeq 2000 platform, having four spor-
adic ALS, twelve familial ALS and eight control samples.
Familial ALS samples and the control samples were used
for the present study to identify the hub genes that can
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act as probable familial ALS targets. Samples were
divided into six groups (Table 1) based on a) presence/
absence of C9orf72 mutation and b) treatment of the
disease with the control/C9orf72 Antisense oligonucleo-
tide (ASO). The four Familial ALS samples having
C9orf72 mutation (Group III) and four control samples
(Group VI) without ASO treatment were put into
network 1 and four familial ALS samples (Group II) and
four control samples (Group IV) treated with the C9orf72
ASOs were put into network 2. All the genes with
RPKM> 5 in atleast one sample were taken for finding
DEGs. The software R v 3.2.2 [18] was used to perform all
the statistical analyses. The Student’s t test statistical
P-values and fold changes were calculated. Further, each
P-value is adjusted with a Benjamini-Hochberg method to
account for multiple testing. The Benjamini-Hochberg
method provides sufficiently conservative estimates of
“significance” among the many statistically detectable
scores. Genes with fold change > 2.0 and < 0.5 and the
adjusted P-value < 0.05 were identified in both the
networks (Additional file 1: Table S1). Gene co-expression
network analysis was performed by constructing a matrix
of pairwise Pearson correlations between all genes identi-
fied by statistical methods across all selected samples.
Finally co-expression threshold of > 0.9 was set to find the
DEGs in both the networks. This study aimed at obtaining
the DEGs for C9orf72 ASO treated samples over ASO
untreated samples.
Enrichment analysis of GO function and KEGG pathway
The information on the networked molecules and genes
is contained in the KEGG. The database for annotation,
visualization and integrated discovery (DAVID) was used
to analyze list of genes derived from high-throughput
genomic experiments. DAVID online tool [19] for Gene
ontology (GO) annotations and KEGG pathway analysis
were used to perform the enrichment analysis of the
biological processes of DEGs in order to identify the
enriched genes at the cellular level. The cut-off criteria
of more than two genes, FDR and P-values less than
0.05 were chosen.
Construction of gene/protein interaction network and
analysis
Human protein – protein interaction network (PPI) data
were obtained from public databases MINT [20], BioGrid
[21] and HPRD [22]. Potential PPI correlations were dem-
onstrated by mapping all the DEGs on the compiled data
set of human interactome for the PPI network construc-
tion and microarray data enrichment analysis. The DEGs
showed to have 1885 interactions reported in the databases
and visualized in CytoHubba [23]. Scale-free property of
the protein interaction network was used to find the key
hub proteins. PPI network was constructed based on the
PPI correlations by the Cytoscape v3.2.0 software platform.
Molecular complex detection analysis
The molecular complex detection (MCODE) algorithm
[24] is a well known automated method using the
Cytoscape MCODE plug-in to find highly interconnected
subgraphs or modules that detects densely connected re-
gions in large PPI networks that may represent molecular
complexes. In the present study, Cytoscape MCODE plug-
in was used to search clustered subnetworks of highly
intraconnected nodes (n > 15). Then the identified modules
were used for functional enrichment analysis using the
BinGO [25] plug-in of Cytoscape. Validation of molecular
mechanism of ALS and finding potentially essential genes
can be performed through these analytical results.
Results
DEGs analysis and Co-expression network
The two networks constructed were used to find the DEGs
that could be probable targets for familial ALS disease. In
the present study network 1 and network 2 were compared
to find highly expressed genes before and after ASO treat-
ment of C9orf72 fibroblasts and control fibroblasts. Statis-
tical analysis has yielded 1055 DEGs. Of these, 734 genes
were upregulated and 321 genes were downregulated
(Additional file 1: Table S1). Statistical methods used in the
present study could identify more number of DEGs when
compared to the DEGs reported by Lagier-Tourenne et al.
[16]. Several important DEGs were identified, including
Tumor necrosis factor (TNF), Endothelin 1 (EDN1), Angio
tensin (AGT), Apolipoprotein E (APOE), Vitronectin (V
TN), Von Willebrand factor (VWF), Thrombospondin
receptor (CD36), TNF Receptor Superfamily Member 5
(CD40), Integrin, Alpha 3 (ITGA3), Integrin, Alpha 7 (IT
GA7), Transforming growth factor beta 2 (TGFB2), Aggre-
can (ACAN),Wingless-Type MMTV Integration site fam
ily, member 5A (WNT5A), Neurotrophic tyrosine kinase,
receptor, type 2 (NTRK2) and Zinc finger protein GLI1
(GLI1) which were involved in the biological processes
related to ALS.
Table 1 Classification of samples into groups based on






1. Group I 4 C9orf72expansion CTRL ASO
2. Group II 4 C9orf72expansion C9orf72 ASO
3. Group III 4 C9orf72expansion No treatment
4. Group IV 4 Non-neurologic control C9orf72 ASO
5. Group V 4 Sporadic ALS No treatment
6. Group VI 4 Non-neurologic control No treatment
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GO function and KEGG pathway enrichment analysis
Functional annotation of large-scale genomic data can
be obtained by GO analysis approach. The DEGs were
mapped to the DAVID database to investigate the func-
tional changes in the ALS diseased patients. DAVID is
the most popular tool in the field of high-throughput
functional annotation that is cited in more than 2000
publications. The top GO enrichment analysis results of
DEGs based on biological process, cellular components
and molecular function are shown in Table 2. According
to the biological processes analysis, upregulated DEGs
were mainly involved in cell adhesion, biological adhe-
sion, cell-cell adhesion and cell-cell signaling. Based on
the molecular function analysis, DEGs were involved in
calcium ion binding activity. In addition, upregulated
DEGs were located in the extracellular matrix (ECM),
extracellular space, extracellular region part. The down-
regulated DEGs were enriched only in the extracellular
region part with FDR 3.3E-08.
Different pathways were identified in the KEGG path-
way enrichment analysis as shown in Table 3. Upregulated
DEGs were mainly involved in ECM-receptor interaction,
focal adhesion, Cell adhesion molecules (CAMs) whereas
the downregulated genes were not enriched in any of the
KEGG pathways.
PPI network construction
PPI network analysis has been a powerful tool for under-
standing the biological responses in health and disease.
In the PPI network, the protein is defined as the node
and the interaction between two nodes is defined as the
edge. The DEGs related to ALS were mapped onto the
reference network obtained from Mint, HPRD and
BioGrid databases (Fig. 1) where the red colour nodes
indicate highly connected ‘hub’ nodes in PPI network.
The resulting network was divided into subnetworks
each of which represented protein subcomplexes or
functional modules. This subnetworking would provide
more specific and detailed information about the PPI
network. The subnetworks were obtained using the
MCODE plug-in implementing the MCODE algorithm
with the k-score value of 2.0, node score cutoff of 0.2,
maximum depth from the seed node of 100 and graphics-
processing-unit-based parallelization to find modules effi-
ciently. A total of 19 modules were found, among which
five modules were detected with the intra-connection
nodes >15 and node score >2.0 (Table 4, Fig. 2). All
clustered modules varied in size comprising a total of 103
proteins and 263 PPIs.
Next, the complete PPI network was visualized in
Cytohubba to find the hub genes with high degree of
connectivity between the nodes. The higher value for
the degree indicate highly connected network and likely
to be more robust. The degree of each node in the
network was calculated by Cytohubba, which identified
hubs as nodes with the degree value >25 (Table 5).
Finally, functional annotation of submodules was pre-
dicted. Most of the hub genes as mentioned in Table 5
were involved in the subnetworks indicating the reliability
of the subnetwork model generated and these hub genes
were primarily corresponding to adhesion, signaling and
Extra cellular matrix as according to the results obtained
from GO enrichment analysis and KEGG pathways with
P-values and FDR in the acceptable range.
Subnetworks 1, 2, 4 and 5 were enriched in the GO
terms related to the chemical component extracellular
region part, extracellular matrix. Subnetworks 1 and 2
were enriched in biological process GO term related to
cell-cell signaling. Subnetwork 4 was enriched in the
biological process related to cell adhesion and biological
adhesion. Subnetwork 3 was not enriched in any of the
GO term. The P-values of all the enriched GO terms
were in the range of 5.4E-17 to 8.9E-03.
KEGG pathway neuroactive ligand receptor interaction
was enriched in Subnetworks 1 and 2. ECM receptor
interaction pathway was enriched in subnetworks 3 and
4. Subnetwork 5 was enriched in focal adhesion pathway.
The P-values of all the enriched KEGG pathways were in
the range of 3.1E-05 to 2.1E-03.
Discussion
In this study, we used the Human Illumina microarray
data to find hub genes associated with C9orf72 mutation
Table 2 Top GO terms significantly enriched with high counts
of DEGs in samples from ALS fibroblasts and control fibroblasts
Term Category Count P-value FDR value Description
GO:0007155 BP 87 2.4E-16 2.2E-09 Cell adhesion
GO:0022610 BP 87 2.6E-16 2.3E-09 Biological adhesion
GO:0007267 BP 65 8.4E-10 3.4E-04 Cell-cell signaling
GO:0007267 BP 39 3.2E-09 2.3E-04 Cell-cell adhesion
GO: 0005576 CC 200 2.1E-23 2.9E-10 Extracellular region
GO:0044421 CC 123 1.4E-22 1.3E-10 Extracellular region
part
GO: 0031012 CC 57 4.6E-15 2.9E-06 Extracellular matrix
GO: 0005615 CC 81 9.6E-13 1.9E-06 Extracellular space
GO:0005509 MF 100 4.2E-15 2.3E-08 Calcium ion
binding
Table 3 Top four enriched KEGG pathways of DEGs with low
P-values in samples from ALS fibroblasts and control fibroblasts
KEGG Count P-value FDR value Description
KEGG_PATHWAY 17 2.0E-06 3.8E-03 Extracellular matrix(ECM)-
receptor interaction
KEGG_PATHWAY 24 9.8E-05 3.7E-02 Focal adhesion
KEGG_PATHWAY 17 6.1E-04 2.7E-02 Cell adhesion
molecules (CAMs)
Kotni et al. Orphanet Journal of Rare Diseases  (2016) 11:148 Page 4 of 9
in FALS disease. C9orf72 expansion was found to be the
most common genetic abnormality in FALS [26]. The
discovery of the expansion repeat in C9orf72 is too recent
[27] to know its complete relationship with the inflamma-
tory system. This repeat expansion has opened new
avenues of research in ALS. A total of 1055 DEGs in
the C9orf72 patient fibroblasts were identified compared to
the control fibroblasts. We could find more number of
DEGs compared to the DEGs reported by Lagier-Tourenne
et al.[16]. The DEGs were mainly enriched in the GO
terms related to cell adhesion, biological adhesion and
cell-cell signaling biological processes, extracellular
matrix and extracellular space cellular components and
the calcium ion signaling molecular function. The path-
ways enriched by the DEGs are ECM receptor interaction
pathway, focal adhesion pathway, cell adhesion molecules.
15 hub genes were identified in the PPI network that was
associated with the GO terms and pathways enriched by
the DEGs (Table 5).
Tumor necrosis factor (TNF), Endothelin 1 (EDN1) were
detected as the main hubs with a degree value of >35. TNF
is a pro-inflammatory cytokine produced by monocytes
and activated by mast cells, fibroblasts and neurons during
acute inflammation. TNF is known to be secreted by the
brain resident macrophage i.e. the microglial cell in
response to various stimuli and its over production is
related to neuronal cell death [28]. Elevated production of
TNF is a common feature of several inflammatory diseases
including ALS. It is known to play a major role in the
central nervous system (CNS) neuroinflammation-media
ted cell death in ALS as well as several other CNS compli-
cations. As a consequence of innate immune activation, an
increased level of TNF is observed in many neurodegenera-
tive diseases as reported earlier [29–32]. Previously, FALS
and SALS affected spinal cord of mice was investigated and
found increased immunoreactivity for TNF. Inhibiting the
expression of TNF was observed in the ALS affected mice
treated with thalidomide and lenalidomide drugs. This
result gave the confirmation of the hypothesis that TNF
plays an important role in the pathogenesis of ALS disease
[33, 34]. The overexpression of TNF is observed in the ALS
disease fibroblast samples taken for the present study with
the fold change of 4.5 compared to the control fibroblast
samples. TNF is involved both in immunological pathways
and in oxidative stress known in ALS disease [35–37].
Hence modulating the levels of TNF would be worthwhile
therapy for various CNS related diseases making TNF as
the therapeutic target for neurodegenerative diseases
including ALS disease.
Fig. 1 PPI network constructed from DEGs on the basis of human interactome (Nodes with higher degree values (hubs) are depicted with large
shape and red colour with continuous gradient mapping to green colour with lower degree value)
Table 4 Statistics for top five subnetworks identified by MCODE
method in PPI network
Subnetwork Score Proteins Interactions
1. 12.105 20 115
2. 5.067 16 38
3. 4.105 20 39
4. 3.875 17 31
5. 3.379 30 40
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Fig. 2 Subnetworks identified from PPI of DEGs. Nodes in violet color are upregulated genes, yellow nodes are downregulated genes and blue
lines are interactions between nodes
Table 5 Top 15 hub nodes identified in PPI network for DEGs from ALS fibroblast samples and control fibroblast samples
Gene Gene Name Degree GO Term
TNF Tumor necrosis factor 47 Celladhesion/Cell-cell adhesion/ECM
EDN1 Endothelin 1 42 Cell-cell signaling/ECM
AGT Angiotensin 37 Celladhesion/Cell-cell signaling/ECM
WNT5A Wingless-Type MMTV Integration site family, member 5A 31 Cell-cell signaling/ECM
APOE Apolipoprotein E 29 Cell-cell signaling
VWF Von Willebrand factor 28 Cell adhesion/ECM
ACAN Aggrecan 24 Celladhesion/Cell-cell adhesion/ECM
CD36 Thrombospondin receptor 24 Cell adhesion
VTN Vitronectin 23 Cell adhesion/ECM
CD40 TNF receptor super family member 5 25 Cell adhesion molecules/Extracellular region
NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 23 Cell-cell signaling
ITGA3 Integrin, alpha 3 21 Cell adhesion/focal adhesion
ITGA7 Integrin, alpha 7 21 Cell adhesion/focal adhesion
GLI1 Zinc finger protein GLI1 19 Cell-cell signaling
TGFB2 Transforming growth factor beta 2 19 Cell-cell signaling
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EDN1 and its receptor B have been previously reported
to be associated with ALS pathology [38]. It is a pro-
inflammatory vasoconstrictor peptide encoding gene
known to exert a variety of ALS-aggravating effects that
includes axonal degeneration [39], heightened sensitivity
to hypoxic stress [40] and increased excitotoxicity [41].
The expression of EDN1 in astrocytes and microglia is
required for their survival under oxidative stress [42]
which is a central mechanism by which motor neuron
death occurs. EDN1 is found to be abundantly expressed
by reactive astrocytes in the spinal cord of mouse model
and SALS patients [43]. Several experiments have been
performed to understand the toxic effects and lower the
levels of EDN1 that would affect the motor neuron cell
death. These experiements would suggest EDN1 as the
potential target for therapeutic invention in ALS [43].
Furthermore, GO functional analysis also demonstrated
that the DEGs were mainly involved in cell adhesion, bio-
logical adhesion, cell-cell signaling based on the analysis
of biological processes. Adhesion plays an important role
in cell signaling, regulation and fundamental in the devel-
opment and maintenance of tissues [44].
Progression of ALS disease was known to involve cell-
to-cell transmission involving motor neurons, microglia
and astrocytes [45, 46].
Substantial clinical and pathological characteristics
overlap among the common neurodegenerative diseases,
ALS, Frontotemporal dementia (FTD) and Alzheimer’s
disease (AD). C9orf72 repeat expansions were found to
be risk factors for ALS, FTD and AD [47, 48]. Kohli et
al. and Beck et al. demonstrated the risk factors of AD
to be C9orf72 repeat expansions [49, 50].
Cell adhesion is involved in many aspects of neuronal
development, including axon-bundle formation, synapse
formation and formation of glial networks that surrounds
axons and synapses [51–53]. The mechanical and chemical
linkages between the intracellular and extracellular space
are formed by cellular adhesions [54]. These adhesion
systems forms the major for brain morphology and highly
coordinated brain functions, such as memory and learning
[51–53]. Various cell adhesion molecules (CAMs) are
involved in the synapse formation and neuron-glia interac-
tions [54]. These adhesions makes the interactions between
the cells and the ECM through the cell adhesion molecules
which also involved in the cell migration and signaling of
many biological processes. This functionality of adhesion
and adhesion molecules has made this a topic of study in
the present scientific community. Previously reports stated
cell adhesion molecules (CAMs) as disease biomarkers or
pharmaceutical targets of neurological diseases [55].
The upregulated genes with highest hub degree mainly
TNF, AGT, VWF, ACAN, VTN, ITGA3, ITGA7 are
enriched in the cell adhesion biological process which
forms the basis for neuronal damage or repair. The cell
adhesion molecules (CAMs) ITGA3, ITGA7, CD36 and
CD40 are differentially expressed which makes the links be-
tween the cells and ECM for cell migration and signaling
cascades of many biological processes. Cell adhesion
had previously been shown to be related to neurodegener-
ative diseases [56] and the CAMs were involved in the
pathogenesis of many neurodegenerative diseases as previ-
ously reported [57, 58]. These CAMs play an important
role in the inflammatory mechanisms associated with
neurodegeneration [59]. Specific ECM molecules bind to
integrin cell surface receptors and lead to downstream
focal adhesion activation involved in the regulation of
cell survival signals. Integrins and focal adhesion CAMs’
studies indicate a role for signaling in neurite outgrowth
differentiation and in response to the toxic effects associ-
ated with neurodegeneration [60, 61].
Neuro active ligand receptor interaction KEGG pathway
is highly enriched in the subnetworks. Many GPCRs are
involved in this pathway. Signal transduction pathways
activated by GPCRs are known to regulate variety of neur-
onal functions, plasticity and synaptic transmission, and
control of various behaviours including memory, learning,
emotions and motor functions. Most of the neurological
disorders involve degeneration and death of neurons in
brain and spinal cord. For example, ALS is characterized by
selective degeneration of motor neurons in the spinal cord.
The causes of neurodegenerative conditions are different in
different diseases, but they do share mechanisms that
include metabolic compromise, oxidative stress and disrup-
tion of cellular calcium homeostasis [62–64]. GPCRs are
expressed in neurons and/or glial cells in central nervous
system affected with neurodegenerative diseases. Increasing
evidences suggest that signaling pathways play an import-
ant role in modifying the neurodegenerative processes.
Previous studies have reported TNF as the therapeutic
target for neurodegenerative [65] and also CAMs have been
reported as targets for many neurodegenerative diseases
[59]. All these forms the important aspects of the central
nervous system hence could be important therapeutic tar-
gets for neurodegenerative diseases including ALS.
Conclusion
In the present study, systems biology approach was used to
examine the relationships between the importance of genes
and several topological characteristics in the human PPI
network. There are many studies previously reported with
the mutations and pathways associated with SOD1 gene
mutation and the pathways involved in its pathogenesis.
We have uncovered gene-expression changes that occurred
in familial ALS with C9orf72 mutation with ASO mediated
reduction of C9orf72 RNAs. In view of this, gene expres-
sion data of C9orf72 fibroblasts and control fibroblasts
were used to identify the DEGs related to ALS. Various
bioinformatic tools were used to find the hub genes,
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enriched GO terms and KEGG pathways. GO terms
related to adhesion, signaling were the main terms
enriched by the DEGs. TNF, EDN1, AGT along with many
other CAMs were identified to be the possible potential
genes as targets for ALS disease. However, further studies
are required to determine the clinical utility of these
observations in the therapeutic management of ALS
related neurological disease.
Additional file
Additional file 1: Differentially Expressed Genes in C9orf72 patients
compared to control individuals fibroblasts. (XLSX 74 kb)
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